Latency, LLC
211Patents
130Active
211Granted
51Portfolio score
Filing activity: Mar 12, 1990 → Aug 3, 2021 · 84 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8126456B2 | Mobile communication device monitoring systems and methods | Electricity | 155 | Active |
| US6329503A | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 91 | Expired |
| US7507541B2 | 36P6D5: secreted tumor antigen | Emerging Cross-Sectional Technologies | 77 | Active |
| US7485299B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 44 | Active |
| US7053186B2 | Antibodies immunospecific for STEAP1 | Emerging Cross-Sectional Technologies | 38 | Expired |
| US5019009A | Toy car chassis intermittent tilt and steering structure | Human Necessities | 34 | Expired |
| US7037667B1 | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer | Physics | 33 | Expired |
| US7361338B2 | Methods to inhibit growth of prostate cancer cells | Chemistry; Metallurgy | 33 | Expired |
| US7494646B2 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins | Chemistry; Metallurgy | 32 | Expired |
| US6833438B1 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 30 | Expired |
| US6887975B2 | Peptides derived from STEAP1 | Emerging Cross-Sectional Technologies | 30 | Expired |
| US7595379B2 | Antibodies and related molecules that bind to PSCA proteins | Physics | 29 | Expired |
| US7166714B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 26 | Expired |
| US8013128B2 | Antibodies and related molecules that bind to PSCA proteins | Physics | 24 | Active |
| US7641905B2 | Methods of inducing an immune response | Human Necessities | 22 | Expired |
| US7628989B2 | Methods of inducing an immune response | Human Necessities | 22 | Expired |
| US7541442B2 | Antibodies and related molecules that bind to PSCA proteins | Physics | 21 | Expired |
| US6943235B1 | Transmembrane protein expressed in prostate cancer | Chemistry; Metallurgy | 21 | Expired |
| US8008442B2 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins | Chemistry; Metallurgy | 19 | Expired |
| US7427399B2 | Antibodies and related molecules that bind to 161P2F10B proteins | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6756036B2 | Methods for treating cancer using PSCA antibodies and fragments thereof | Physics | 18 | Expired |
| US7947276B2 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins | Chemistry; Metallurgy | 17 | Active |
| US7622564B2 | Prostate stem cell antigen (PSCA) variants and subsequences thereof | Emerging Cross-Sectional Technologies | 17 | Active |
| US7575749B2 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7459539B2 | Antibody that binds zinc transporter protein 108P5H8 | Emerging Cross-Sectional Technologies | 16 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.